Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13511482 | 0.88 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL13507589 | 0.81 | MEN1 (0.38) | ALDH1A1MEN1 | |
| SCHEMBL13508064 | 0.77 | PGR (0.39) | — | |
| SCHEMBL25026632 | 0.76 | CYP11B2 (0.57) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL27856084 | 0.75 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL13507715 | 0.74 | APP (0.33) | — | |
| SCHEMBL13507601 | 0.74 | AKT1 (0.46) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL13507747 | 0.73 | ACHE (0.33) | MEN1 | |
| SCHEMBL13507670 | 0.73 | AKT1 (0.46) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL13507616 | 0.73 | RXRA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | CYP11B2 781/4885CYP11B1 720/4885CYP1A2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.